Harvard Bioscience (HBIO)
(Delayed Data from NSDQ)
$0.51 USD
+0.02 (4.66%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $0.50 -0.01 (-0.99%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth NA Momentum NA VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HBIO 0.51 +0.02(4.66%)
Will HBIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HBIO
Zacks Industry Outlook Highlights Mettler-Toledo International and Harvard Bioscience
2 Instruments Stocks to Watch From a Challenging Industry
HBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for HBIO
Harvard Bioscience Schedules Second Quarter 2025 Earnings Conference Call for August 11, 2025 ...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Harvard Bioscience announces CEO succession plan
Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent ...
Harvard Bioscience (HBIO) Announces CEO Transition for July 2025 | HBIO Stock News